News Ipsen to buy rare disease firm Clementia for up to $1.31bn France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
News European Commission approves 2nd IPCEI to sum of €403m The European Commission has approved, under EU State aid rules, the second health-related IPCEI to support innovations in medical devices.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
